Eline A M Ruigrok
Overview
Explore the profile of Eline A M Ruigrok including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
134
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van der Heide C, Campeiro J, Ruigrok E, van den Brink L, Ponnala S, Hillier S, et al.
EJNMMI Res
. 2024 Dec;
14(1):125.
PMID: 39718718
Background: Fibroblast activation protein (FAP) is an attractive target for cancer theranostics. Although FAP-targeted nuclear imaging demonstrated promising clinical results, only sub-optimal results are reported for targeted radionuclide therapy (TRT)....
2.
Verhoeven M, Ruigrok E, van Leenders G, van den Brink L, Balcioglu H, van Weerden W, et al.
Front Oncol
. 2023 Sep;
13:1199432.
PMID: 37719014
Introduction: Central to targeted radionuclide imaging and therapy of prostate cancer (PCa) are prostate-specific membrane antigen (PSMA)-targeting radiopharmaceuticals. Gastrin-releasing peptide receptor (GRPR) targeting has been proposed as a potential additional...
3.
Ruigrok E, Verhoeven M, Konijnenberg M, de Blois E, de Ridder C, Stuurman D, et al.
Eur J Nucl Med Mol Imaging
. 2022 Aug;
49(13):4440-4451.
PMID: 35951084
Purpose: The radiolabeled gastrin-releasing peptide receptor (GRPR)-targeting antagonist NeoB is a promising radioligand for imaging and therapy of GRPR-expressing malignancies. In the current study, we aimed to discover the target...
4.
Ruigrok E, Verkaik N, de Blois E, de Ridder C, Stuurman D, Roobol S, et al.
Int J Mol Sci
. 2022 Jul;
23(14).
PMID: 35887398
Prostate specific membrane antigen targeted radionuclide therapy (PSMA-TRT) is a promising novel treatment for prostate cancer (PCa) patients. However, PSMA-TRT cannot be used for curative intent yet, thus additional research...
5.
Correction to: In vitro dose effect relationships of actinium‑225‑ and lutetium‑177‑labeled PSMA‑I&T
Ruigrok E, Tamborino G, de Blois E, Roobol S, Verkaik N, De Saint-Hubert M, et al.
Eur J Nucl Med Mol Imaging
. 2022 May;
49(11):3956-3957.
PMID: 35614268
No abstract available.
6.
Ruigrok E, Tamborino G, de Blois E, Roobol S, Verkaik N, De Saint-Hubert M, et al.
Eur J Nucl Med Mol Imaging
. 2022 May;
49(11):3627-3638.
PMID: 35556158
Purpose: Targeting the prostate-specific membrane antigen (PSMA) using lutetium-177-labeled PSMA-specific tracers has become a very promising novel therapy option for prostate cancer (PCa). The efficacy of this therapy might be...
7.
Ruigrok E, van Vliet N, Dalm S, de Blois E, van Gent D, Haeck J, et al.
Eur J Nucl Med Mol Imaging
. 2020 Oct;
48(5):1339-1350.
PMID: 33094433
Purpose: Various radiolabeled prostate-specific membrane antigen (PSMA)-targeting tracers are clinically applied for prostate cancer (PCa) imaging and targeted radionuclide therapy. The PSMA binding affinities, biodistribution, and DNA-damaging capacities of these...
8.
Tamborino G, De Saint-Hubert M, Struelens L, Seoane D, Ruigrok E, Aerts A, et al.
EJNMMI Phys
. 2020 Feb;
7(1):8.
PMID: 32040783
Background: Survival and linear-quadratic model fitting parameters implemented in treatment planning for targeted radionuclide therapy depend on accurate cellular dosimetry. Therefore, we have built a refined cellular dosimetry model for...
9.
Ruigrok E, van Weerden W, Nonnekens J, de Jong M
Pharmaceutics
. 2019 Nov;
11(11).
PMID: 31671763
Prostate specific membrane antigen (PSMA) has become a major focus point in the research and development of prostate cancer (PCa) imaging and therapeutic strategies using radiolabeled tracers. PSMA has shown...